「auditing」の検索結果

INVOKE THIS SKILL when routing a LangGraph agent with a decision model (TypeSafe Jev, SemIf) instead of an LLM, or when auditing an existing agent for LLM calls that only produce a routing decision. Covers langchain-typesafe Noul/Choice/Score, reading answers correctly, threshold design, and LangSmith Gateway wiring.

日本語の概要は準備中です。原文の説明を表示しています。

WCAG 2.2 Accessibility Audit skill that systematically evaluates web pages against 8 core Success Criteria (1.1.1, 1.4.3, 1.4.11, 2.1.1, 2.1.2, 2.4.3, 2.4.7, 4.1.2) using accessibility tree inspection and visual analysis. Use this skill when you need to perform accessibility testing/auditing on a live webpage.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing AISTATS experiments, simulations, baselines, statistical tests, uncertainty estimates, ablations, random seeds, hyperparameters, compute, dataset handling, and claim-to-evidence fit, with emphasis on experiments that validate theorems rather than chase leaderboards.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an AISTATS submission for OpenReview readiness, abstract/full-paper deadlines, the 8-page submission body, double-blind anonymity, supplementary material, reproducibility checklist, dual-submission policy, reviewer volunteer requirements, desk-reject triggers, and final-week submission sequencing.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing figures for an Advanced Materials manuscript, including the lead figure, multi-panel characterization figures, and the Table-of-Contents graphic, where visual quality is a house expectation. Designs figure strategy; does not run the analysis or write prose.

日本語の概要は準備中です。原文の説明を表示しています。

Use when building or auditing the related-work section of an ACM MM (ACM Multimedia) paper — covering the multimedia literature spread across vision, audio/speech, language, HCI/QoE, and systems, handling arXiv-speed concurrency, keeping citations double-blind, and verifying that cited "ACM MM papers" are ACM MM and not ICMR, MMSys, CVPR, or TOMM.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing the experiments of an ACM MM (ACM Multimedia) paper — matched baselines per modality, ablations that isolate the cross-modal fusion, user studies or QoE measurement where the claim is subjective, dataset and media licensing, and honest compute reporting, so evidence supports a multimedia claim.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an ACM MM (ACM Multimedia) submission for OpenReview readiness — thematic-area choice, the 6-8 page ACM sigconf budget, references-only overflow, double-blind anonymity versus the single-blind Reproducibility/Open-Source/Dataset tracks, supplementary media, dual submission, desk-reject triggers, and last-week sequencing.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing ACM CCS experiments, attack demonstrations, adaptive-attack defense evaluations, security measurements, baselines, overhead and cost reporting, ablations, and claim-to-evidence fit, with emphasis on evidence that survives an adversarial program committee rather than leaderboard wins.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an ACM CCS submission for HotCRP readiness, dual-cycle abstract registration and full-paper deadlines, the 12-page ACM sigconf body, anonymization, the ethics considerations appendix, artifact-availability posture, dual-submission policy, per-cycle submission caps, desk-reject triggers, and final-week sequencing.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an ACL submission before an ACL Rolling Review cycle deadline, covering long/short paper page budgets, the mandatory Limitations section, Responsible NLP checklist, anonymized PDFs and supplements, preprint declarations, dual-submission rules, resubmission linking, and ARR desk-reject triggers on OpenReview.

日本語の概要は準備中です。原文の説明を表示しています。

Use when strengthening reproducibility evidence for an ACL paper reviewed through ACL Rolling Review, covering the Responsible NLP checklist end to end, hyperparameter and compute reporting, prompt and decoding disclosure for LLM experiments, data contamination auditing, variance across runs, and checklist-to-paper consistency.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing experiments for an ACL paper, covering tuned LLM baselines, multi-dataset and multilingual evaluation, statistical significance and variance, human evaluation with agreement reporting, contamination and prompt-sensitivity controls, ablations, and error-analysis expectations in NLP reviewing.

日本語の概要は準備中です。原文の説明を表示しています。

Use when constructing or auditing accounting measures for 《会计研究》 (Accounting Research) — discretionary accruals (modified Jones), real earnings management (Roychowdhury), conservatism (Basu / C-Score), comparability, disclosure indices, audit-quality and tax-avoidance proxies — so each measure is built transparently and reproducibly. Use before identification.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing AAAI experiments for the broad-AI program committee, including baselines, ablations, statistical significance, robustness, human evaluation, AI-for-Social-Impact and alignment/safety evidence, compute and cost reporting, and reproducibility-checklist alignment for Phase-1 survival.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an AAAI main technical track submission for OpenReview readiness, double-blind anonymity, page limits, reproducibility checklist, supplementary material, author limits, multiple-submission policy, and AAAI AI-use policy compliance.

日本語の概要は準備中です。原文の説明を表示しています。

Use when designing or auditing AAMAS experiments - self-play and population-based training, opponent selection, equilibrium and regret metrics, game-theoretic simulations, ablations, seeds, hyperparameters, compute, and claim-to-evidence fit - with emphasis on experiments that probe the interaction rather than chase a single-agent leaderboard.

日本語の概要は準備中です。原文の説明を表示しています。

Use when auditing an AAMAS main-track submission for OpenReview readiness, the 8-page-plus-references limit, the full-paper versus 2-page extended-abstract choice, double-blind anonymity, the supplementary zip cap, track fit across the AAAI/JAAMAS/Blue Sky tracks, dual-submission rules, and desk-reject triggers before upload.

日本語の概要は準備中です。原文の説明を表示しています。

Treats a ctDNA assay as a molecule-counting experiment at the Poisson edge and builds its analytical-validation case the measurement-science way. Covers the genome-equivalent currency (~330 haploid copies/ng), the lambda = input_GE x VAF sampling ceiling (lambda>=3 for ~95% detection), the error-suppression ladder (raw NGS ~1e-3 -> single-strand UMI ~1e-4/1e-5 -> duplex <1e-7), the CLSI EP17 LoB/LoD/LoD95/LoQ framework, the per-locus-vs-panel-integrated LoD distinction that lets bespoke MRD reach ppm, contrived/SEQC2 reference standards, and honest LoD reporting conditioned on input mass + consensus depth + replicate detection rate. Use when stating or trusting a sensitivity claim, designing a dilution-series validation, deciding how many genome equivalents are needed at a target VAF, choosing a single-locus vs panel-integrated LoD, or auditing a "detects 0.1% VAF" claim.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritizes rare-disease variants from trio/quad WES/WGS with de novo (DeNovoGear, Triodenovo), compound-heterozygous phasing (WhatsHap), mosaic VAF tiering, phenotype-driven ranking (Exomiser, Phen2Gene, AMELIE), ClinGen gene-disease validity gating, and ACMG SF v3.2 secondary findings reporting. Use when running diagnostic exome / genome pipelines, identifying candidate Mendelian disease genes, screening for incidental findings, or auditing VUS reclassification cycles. The ACMG/AMP classification framework (PVS1 decision tree, Pejaver PP3/BP4 calibration, Tavtigian point system) is in clinical-databases/acmg-classification.

日本語の概要は準備中です。原文の説明を表示しています。

Constructs and validates polygenic risk scores using LDpred2-auto, SBayesRC, MegaPRS, PRS-CS, PROSPER, MUSSEL, BridgePRS, JointPRS, PRSmix, or PGS Catalog Calculator with ancestry-aware reference panels (HapMap3, UKB-LD), ancestry-conditional calibration, and PRS-RS reporting standards. Use when computing PRS for cohorts, applying absolute-risk transformation, assessing cross-ancestry portability (Martin 2017 / Ding 2023 continuous ancestry), or auditing PRS manuscripts against the 22-item PRS-RS reviewer checklist.

日本語の概要は準備中です。原文の説明を表示しています。

Extracts and assigns COSMIC v3.4 mutational signatures (86 SBS / 11 DBS / 18 ID / 21 CN / 16 SV) from somatic VCFs using SigProfilerSuite, MutationalPatterns, MuSiCal mvNMF, SigNet, or HRDetect. Use when characterizing DNA-damage etiology (BRCA1/2 HRD, MMR-D, POLE, APOBEC3A, UV, tobacco, aflatoxin, 5-FU/SBS17b, platinum, colibactin SBS88), routing PARP inhibitor decisions, or auditing de novo extraction vs refit choice for cohort size.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates tumor mutational burden from WES/WGS/panel data with Friends of Cancer Research harmonization equations, per-assay calibration (FDA 10/Mb = 7.8 TSO500 = 8.4 OncomineTML), synonymous/indel/germline filtering, hypermutator tiering, blood TMB, and integration with HLA-LOH and neoantigen quality (Luksza 2017 fitness). Use when assessing ICI eligibility under tumor-specific cutoffs (McGrail 2021), comparing tissue vs bTMB, or auditing TMB-H reporting against ESMO 2024 and FDA pembrolizumab pan-tumor 2020.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses ChIP-seq quality across antibody specificity, fragmentation, enrichment, replicate concordance, and library complexity. Computes FRiP, NSC/RSC (phantompeakqualtools), library complexity (NRF/PBC1/PBC2), deepTools plotFingerprint (JS distance, AUC, synthetic JS), ChIPQC, IDR with ENCODE Nself/Nt rules, and detects hyper-ChIPable artifacts. Use when validating an antibody, diagnosing failed peak calls, deciding whether to proceed with downstream analysis, grading against ENCODE thresholds, or auditing replicate concordance.

日本語の概要は準備中です。原文の説明を表示しています。